Show simple item record

dc.contributor.authorChau, I
dc.date.accessioned2017-07-05T10:33:23Z
dc.date.issued2017-10
dc.identifier.citationClinical cancer research : an official journal of the American Association for Cancer Research, 2017, 23 (20), pp. 6002 - 6011
dc.identifier.issn1078-0432
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/678
dc.identifier.eissn1557-3265
dc.identifier.doi10.1158/1078-0432.ccr-17-0020
dc.description.abstractGastrointestinal (GI) cancers are among the most deadly malignancies. Although serial incremental survival benefits have been made with cytotoxic chemotherapy with metastatic disease, a plateau of achievement has been reached. Applying modern integrative genomic technology, distinct molecular subgroups have been identified in GI cancers. This not only highlighted the heterogeneity in tumors of each primary anatomical site but also identified novel therapeutic targets in distinct molecular subgroups and might improve the yield of clinical success. Molecular characteristics of tumors and their interaction with the tumor microenvironment would further affect development of combination therapy, including immunotherapy. Currently, immune checkpoint blockade attracts the most intense research, and the successful integration of these novel agents in GI cancers in the treatment paradigm requires an in-depth understanding of the diverse immune environment of these cancers. <i>Clin Cancer Res; 23(20); 6002-11. ©2017 AACR</i>.
dc.formatPrint-Electronic
dc.format.extent6002 - 6011
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectHumans
dc.subjectGastrointestinal Neoplasms
dc.subjectTreatment Outcome
dc.subjectImmunotherapy
dc.subjectCombined Modality Therapy
dc.subjectClinical Trials as Topic
dc.subjectMolecular Targeted Therapy
dc.subjectProgrammed Cell Death 1 Receptor
dc.subjectBiomarkers, Tumor
dc.subjectAntineoplastic Agents, Immunological
dc.subjectB7-H1 Antigen
dc.titleClinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes.
dc.typeJournal Article
dcterms.dateAccepted2017-06-09
rioxxterms.versionofrecord10.1158/1078-0432.ccr-17-0020
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2017-10
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfClinical cancer research : an official journal of the American Association for Cancer Research
pubs.issue20
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume23en_US
pubs.embargo.termsNot known
dc.contributor.icrauthorChau, Ian
dc.contributor.icrauthorMarsden,


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record